1. Home
  2. Knowledge Base
  3. References
  4. Tomoregulin internalization confers selective cytotoxicity of immunotoxins on prostate cancer cells.

Tomoregulin internalization confers selective cytotoxicity of immunotoxins on prostate cancer cells.

Zhao XY, Liu HL, Liu B, Willuda J, Siemeister G, Mahmoudi M, Dinter H (2008) Tomoregulin internalization confers selective cytotoxicity of immunotoxins on prostate cancer cells. Transl Oncol 1:102-109. doi: 10.1593/tlo.08124

Summary: Tomoregulin is a type 1 transmembrane protein with a short cytoplasmic tail, and is found in the brain and prostate. After confirming cell surface localization by flow cytometry, and determining expression levels by whole-cell binding assays, the authors evaluated the use of tomoregulin as a target for immunotoxin therapy. Cells transfected with tomoregulin were treated with anti-tomoregulin + Mab-ZAP (IC50 = 160 pM; Cat. #IT-04) in vitro. The results demonstrate the potential for tomoregulin in prostate cancer treatment.

Related Products: Mab-ZAP (Cat. #IT-04)